Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

166.62 +2.24 (+1.36%)
Streaming Delayed Price Updated: 1:53 PM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,215,931
Open 164.84
Bid (Size) 166.60 (2)
Ask (Size) 166.64 (2)
Prev. Close 164.38
Today's Range 164.47 - 167.41
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report." 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga

Performance

YTD
+4.16%
+4.16%
1 Month
+3.74%
+3.74%
3 Month
+13.25%
+13.25%
6 Month
+3.34%
+3.34%
1 Year
+2.43%
+2.43%

More News

Read More
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
Via Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Analyzing NYSE:JNJ's Dividend Potential.
Via Chartmill
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
Via Chartmill
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
Via The Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
Via Benzinga
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
Via Benzinga
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
Via The Motley Fool
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
Via Talk Markets
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Via Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Via Benzinga
Exposures Product Safety
12 Dividend Stocks to Earn Income Every Month
Via The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
Via The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Via Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Via Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
Via The Motley Fool
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.